目的 探讨肾康注射液联合替米沙坦和盐酸贝那普利治疗糖尿病肾病的临床疗效。方法 选取2014年1月-2015年10月上海市浦东新区人民医院肾脏内科收治的糖尿病肾病患者94例,随机分为对照组和治疗组,每组各47例。对照组口服盐酸贝那普利片,10 mg/次,1次/d;同时口服替米沙坦片,40 mg/次,1次/d。治疗组在对照组治疗基础上静脉滴注肾康注射液,100 mL加入250 mL生理盐水,1次/d。两组患者均连续治疗4周。观察两组的临床疗效,比较两组治疗前后血肌酐(Scr)、血尿素氮(BUN)、24 h尿蛋白(24 h Upro)、收缩压(SBP)、舒张压(DBP)、尿白蛋白排泄率(UAER)、内生肌酐清除率(Ccr)、QLQ-C评分、KPS评分和HAD评分的变化情况。结果 治疗后,对照组和治疗组的总有效率分别为78.72%、93.62%,两组比较差异有统计学意义(P<0.05)。治疗后,两组患者Scr、BUN、24 h Upro、SBP、DBP、UAER、HAD评分均较同组治疗前明显降低,Ccr、QLQ-C评分、KPS评分较治疗前升高,同组治疗前后差异有统计学意义(P<0.05);治疗后治疗组Scr、BUN、24 h Upro、UAER、Ccr、HAD评分、QLQ-C评分、KPS评分的改善程度优于对照组,两组比较差异有统计学意义(P<0.05)。结论 肾康注射液联合替米沙坦和盐酸贝那普利治疗糖尿病肾病具有较好的临床疗效,可有效改善患者的肾功能,提高患者的生活质量和活动状态,有利于患者负面情绪的缓解,具有一定的临床推广应用价值。

Objective To investigate the clinical efficacy of Shenkang Injection combined with telmisartan and benazepril hydrochloride in treatment of diabetic nephropathy.Methods Patients (94 cases) with diabetic nephropathy in Department of Nephrology of People's Hospital of Pudong New Area in Shanghai from January 2014 to October 2015 were randomly divided into control and treatment groups. Each group had 47 cases. The patients in the control group were poadministered with Benazepril Hydrochloride Tablets, 10 mg/time, once daily, and they were poadministered with Telmisartan Tablets, 40 mg/time, once daily. The patients in the treatment group were ivadministered with Shenkang Injection on the basis of the control group, 100 mL added into 250 mL normal saline, once daily. The patients in two groups were treated for 4 weeks. After treatment, the efficacy was evaluated, and the changes of Scr, BUN, 24 h Upro, SBP, DBP, UAER, Ccr, QLQ-C score, KPS score and HAD score in two groups were compared.Results After treatment, the efficacies in the control and treatment groups were 78.72% and 93.62%, respectively, and there were differences between two groups (P < 0.05). After treatment, Scr, BUN, 24 h Upro, SBP, DBP, UAER, and HAD scores in two group were significantly decreased, and Ccr, QLQ-C scores and KPS scores were significantly increased, and the difference was statistically significant in the same group (P < 0.05). After treatment, the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05).Conclusion Shenkang Injection combined with telmisartan and benazepril hydrochloride has clinical curative effect in treatment of diabetic nephropathy, and can effectively improve the kidney function, and can increase the life quality and active, also can remit negative emotions, which has a certain clinical application value.